Approved October 1997
benign prostatic hypertrophy (BPH)
Urology & Kidneys
FLOMAX has been approved for the treatment of benign prostatic hypertrophy (BPH). Boehringer Ingelheim, which licensed the product from originator Yamanouchi, will market the product in the U.S.
The FLOMAX drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.